Global Atopic Dermatitis Market Report: 2016 Edition - New Report by Koncept Analytics

DELHI, India - June 21, 2016 - PRLog -- Atopic dermatitis (AD) is a chronic, inflammatory skin disease of unknown origin that usually starts in early infancy, but also affects a substantial number of adults. Atopic dermatitis is a type of chronic eczematous skin disease. The disease may be inherited and genetically determined. The symptoms of atopic dermatitis are itching, red to brownish grey patches and small raised bumps. The main cause of atopic dermatitis is unknown but it is assumed to be caused due to genetics, dry skin and environmental conditions

There has been no specified biologic till now for atopic dermatitis. It is expected that dupilumab developed by Sanofi will be the first biologic to be used in the treatment of atopic dermatitis. Other prominent competitors entering the market are nemolizumab by Chugai, lebrikizumab by Roche and Tralokinumab by AZN (AstraZeneca). Multiple companies promoting their products could result in faster market expansion. Multiple factors can trigger or worsen atopic dermatitis, including low humidity, seasonal allergies, exposure to harsh soaps and detergents, and cold weather. Since atopic dermatitis affects every age group and is prevalent across every part of the world this industry is projected to grow big after the launch of the biologics.

As per the report "Global Atopic Dermatitis Market: 2016 Edition" by Koncept Analytics, the demand for market will be driven by increase in global population, improvement in the global health care expenditure, accelerated economic growth, pollution and climatic factors and role of triggers. Some of the noteworthy trends and developments of this industry are introduction of new biologics, biomarker in atopic dermatitis and opportunity for new entrants. However, the expansion of atopic dermatitis market is hindered by time to be taken in drug adoption, high price and legal regulations.

The report by Koncept Analytics presents an in-depth analysis of the global market along with a focus on all major regions. A thorough analysis has been conducted on key market players covering their business overview, product portfolio, financial overview and business strategies.

List of Charts

Atopic Dermatitis Treatment Algorithm
Global Atopic Dermatitis Treatment Forecast by Value (2017E-2025E)
Global Adults Affected with Atopic Dermatitis (2015-2025E)
Global Adults Diagnosed with Atopic Dermatitis (2015-2025E)
Global Adults with Moderate to Severe Atopic Dermatitis (2015-2025E)
Global Adults from Adult Refractory to Topical Therapies (2015-2025E)
The US Atopic Dermatitis Treatment Forecast by Value (2017E-2025E)
The US Adults Affected with Atopic Dermatitis (2015-2025E)
The US Adults Diagnosed with Atopic Dermatitis (2015-2025E)
The US Adult with Moderate to Severe Atopic Dermatitis (2015-2025E)
The US Adult Refractory to Topical Therapies (2015-2025E)
The US Treated Patients by Volume (2017E-2025E)
Severity Level for Atopic Dermatitis Patients for less than 5 years (2015)
Severity Level for Atopic Dermatitis Patients for 5 - 18 years (2015)
Severity Level for Atopic Dermatitis Patients for Greater than 18 years (2015)
Time Duration of Infection (2015)
Market Share of People Receiving Treatment (2015)
EU Atopic Dermatitis Treatment Forecast by Value (2018E-2025E)
EU Adults Affected with Atopic Dermatitis (2015-2025E)
EU Adults Diagnosed with Atopic Dermatitis (2015-2025E)
EU Adults with Moderate to Severe Atopic Dermatitis (2015-2025E)
EU Adult Refractory to Topical Therapies (2015-2025E)
EU Treated Patients by Volume (2018E-2025E)
ROW Atopic Dermatitis Treatment Forecast by Value (2017E-2025E)
ROW Adults with Moderate to Severe Atopic Dermatitis (2015-2025E)
ROW Adults Refractory to Topical Therapies (2015-2025E)
Global Population (2006-2015)
Global Health Care Expenditure (2007-2015E)
Improving Global GDP (2007-2015E)
Global Urban Population (2007-2015E)
Global Dupilumab Market by Value (2017E-2025E)
The US Dupilumab Market by Value (2017E-2025E)
European Union Dupilumab Market by Value (2018E-2025E)
Global Nemolizumab Market by Value (2019E-2025E)
The US Nemolizumab Market by Value (2019E-2025E)
European Union Nemolizumab Market by Value (2020E-2025E)
Global Lebrikizumab Market by Value (2019E-2025E)
The US Lebrikizumab Market by Value (2019E-2025E)
European Union Lebrikizumab Market by Value (2020E-2025E)
Global Tralokinumab Market by Value (2019E-2025E)
The US Tralokinumab Market by Value (2019E-2025E)
European Union Tralokinumab Market by Value (2020E-2025E)
Sanofi's Revenue Share by Segment (2015)
Sanofi's Revenue Share by Geography (2015)
Sanofi's Revenue and Net Income (2011-2015)
GSK's Revenue Share by Segment (2015)
GSK's Revenue Share by Geography (2015)
GSK's Revenue and Net Income (2011-2015)
AstraZeneca's Revenue Share by Segment (2015)
AstraZeneca's Revenue Share by Geography (2015)
AstraZeneca's Revenue and Net Income (2011-2015)
Roche's Revenue Share by Segment (2015)
Roche's Sales and Net Income (2011-2015)

List of Tables

Treatments Received by Patients
Pipeline Biologics for Atopic Dermatitis Treatment

Note:  Purchase by Section Also Available

For more Information:

http://www.konceptanalytics.com/Researchreport/global-atopic-dermatitis-market-report-2016-edition-11276.aspx

Koncept Analytics

Vikas Gupta

(Business Development Manager)

FFCS-36, Ansal Plaza

Vaishali, Ghaziabad

U.P - 201010

Tele: +91-120-4130959

Mobile: +91-9811715635

Mail ID - vikas@konceptanalytics.com

Koncept Analytics is a market research company. We are in the field of Market Research from last 10 Years. We do research in telecommunication, healthcare, pharmaceutical, financial services, energy, technology, real estate, logistics, food & beverages and media sectors. For more information:

http://www.konceptanalytics.com